Axel Sjöblad, Managing Director of BioGaia AB, answers the following questions regarding Q1 2018:
- How do you want to summarize the development of the first quarter 2018?
- Two published new meta-analysis have investigated the effect of BioGaia’s drops for infant colic. Can you comment on the results?
- BioGaia has completed a number of launched during the quarter. Which ones do you want to highlight?
- A temporary disruption affect the production of Easy dropper. Which markets are affected by this?
- EBIT remained unchanged Y/Y and was affected by changed accounting principles. Van you tell us more about this?
- BioGaia has expanded its ownership in MetaboGen. What does this mean for the Group financially?
